Tiziana Life Sciences PLC
Tiziana Life Sciences plc, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology, inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. The company is also developing Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients. It has a collaboration agreement with FHI Clinical to conduct a Phase 2 clinical trials for treating hospitalized severe COVID-19 patients with intranasal foralumab. The company was incorporated in 1998 and is based in London, the United Kingdom. Show More...
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 1.36 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2009-12 2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 TTM Earnings Per Share GBP -40.5 -73.51 -3.3 -2.25 -0.73 -0.47 -0.46 -0.32 -0.23 -0.24 Dividends GBP Payout Ratio % * Shares Mil 5.0 18.0 19.0 21.0 26.0 26.0 Book Value Per Share * USD -0.15 -0.11 Free Cash Flow Per Share * USD -0.24 Return on Assets % -39.34 -220.44 -94.59 -181.14 -254.96 -271.46 -147.43 -100.8 -196.75 -172.97 -359.35 Financial Leverage (Average) 1.43 1.69 1.19 1.38 1.09 1.52 13.33 Return on Equity % -57.19 -333.63 -137.82 -269.28 -430.41 -167.92 -121.98 -830.17 Return on Invested Capital % -54.72 -333.63 -137.82 -269.28 -338.96 -161.13 -117.6 -647.85 Interest Coverage -188.5 -509.0 -958.11 Current Ratio 0.4 4.62 0.2 0.46 3.6 12.4 2.89 0.52 1.08 0.32 Quick Ratio 0.2 4.55 0.15 0.28 3.6 12.4 2.77 0.05 0.87 0.14 Debt/Equity